| Biomarker ID | 1311 |
| PMID | 24411283 |
| Year | 2014 |
| Biomarker | LMTK2 [SNP: rs6465657] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Decreased risk of PCa Specific Mortality |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.90 (95% CI: 0.82–0.98) |
| Effect on Pathways | Pathways include: IGF1R human kinase ARCHS4 coexpression, BRAF human kinase ARCHS4 coexpression, WNK2 human kinase ARCHS4 coexpression, PDPK1 human kinase ARCHS4 coexpression, WNK1 human kinase ARCHS4 coexpression |
| Experiment | PCa Specific Mortality Vs No Mortality |
| Type of Biomarker | Prognostic |
| Cohort | 8 different cohorts from The Breast and Prostate Cancer Cohort Consortium were studied in this analysis. Overall 10487 cases were included out of which 1053 had PCa related deaths |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.02 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |